Literature DB >> 21962993

Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study).

José Hermida1, Faye L Lopez, Ramón Montes, Kunihiro Matsushita, Brad C Astor, Alvaro Alonso.   

Abstract

High-sensitivity C-reactive protein (hs-CRP) is a marker for the risk of cardiovascular and overall mortality. However, information about the association between hs-CRP and mortality in patients with atrial fibrillation is scarce. A total of 293 participants of the Atherosclerosis Risk In Communities study with a history of AF and hs-CRP levels available were studied. During a median follow-up of 9.4 years, 134 participants died (46%). The hazard ratio of all-cause mortality associated with the highest versus the lowest tertile of hs-CRP was 2.52 (95% confidence interval 1.49 to 4.25) after adjusting for age, gender, history of cardiovascular diseases, and cardiovascular risk factors. A similar trend was observed for cardiovascular mortality (57 events; hazard ratio 1.90, 95% confidence interval 0.81 to 4.45). The Congestive heart failure, Hypertension, Age >75 years, Diabetes, and previous Stroke or transient ischemic attack (CHADS2) score was also associated with all-cause and cardiovascular mortality, with an adjusted hazard ratio of 3.39 (95% confidence interval 1.91 to 6.01) and 8.71 (95% confidence interval 2.98 to 25.47), respectively, comparing those with a CHADS2 score >2 versus a CHADS2 score of 0. Adding hs-CRP to a predictive model including the CHADS2 score was associated with an improvement of the C-statistic for total mortality (from 0.627 to 0.677) and for cardiovascular mortality (from 0.700 to 0.718). In conclusion, high levels of hs-CRP constitute an independent marker for the risk of mortality in patients with atrial fibrillation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962993      PMCID: PMC4062871          DOI: 10.1016/j.amjcard.2011.08.010

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

2.  Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Alanna M Chamberlain; Sunil K Agarwal; Marietta Ambrose; Aaron R Folsom; Elsayed Z Soliman; Alvaro Alonso
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

3.  Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience.

Authors:  A D White; A R Folsom; L E Chambless; A R Sharret; K Yang; D Conwill; M Higgins; O D Williams; H A Tyroler
Journal:  J Clin Epidemiol       Date:  1996-02       Impact factor: 6.437

4.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

Authors:  W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar
Journal:  Stroke       Date:  1999-04       Impact factor: 7.914

5.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Lloyd E Chambless; Merle Myerson; Kenneth K Wu; A Richey Sharrett; Eric Boerwinkle
Journal:  Arch Intern Med       Date:  2005-11-28

6.  Incidence of and risk factors for atrial fibrillation in older adults.

Authors:  B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation.

Authors:  Dwayne S g Conway; Peter Buggins; Elizabeth Hughes; Gregory Y H Lip
Journal:  Am Heart J       Date:  2004-09       Impact factor: 4.749

8.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

Authors:  G Liuzzo; L M Biasucci; J R Gallimore; R L Grillo; A G Rebuzzi; M B Pepys; A Maseri
Journal:  N Engl J Med       Date:  1994-08-18       Impact factor: 91.245

View more
  17 in total

1.  Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study.

Authors:  Wesley T O'Neal; Elsayed Z Soliman; George Howard; Virginia J Howard; Monika M Safford; Mary Cushman; Neil A Zakai
Journal:  Atherosclerosis       Date:  2015-09-08       Impact factor: 5.162

Review 2.  Role of inflammation in atrial fibrillation pathophysiology and management.

Authors:  Masahide Harada; David R Van Wagoner; Stanley Nattel
Journal:  Circ J       Date:  2015-02-16       Impact factor: 2.993

Review 3.  Inflammation, a link between obesity and atrial fibrillation.

Authors:  Alina Scridon; Dan Dobreanu; Philippe Chevalier; Răzvan Constantin Şerban
Journal:  Inflamm Res       Date:  2015-05-01       Impact factor: 4.575

Review 4.  The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic.

Authors:  David D McManus; Jane S Saczynski; Jeanine A Ward; Khushleen Jaggi; Peter Bourrell; Chad Darling; Robert J Goldberg
Journal:  J Atr Fibrillation       Date:  2012-06-15

5.  A Circulating Biomarker Risk-Prediction Model Correlates with CHADS-2 Risk Score in Chronic Atrial Fibrillation.

Authors:  Smita I Negi; Ian Greener; Aashish Anand; Samuel C Dudley
Journal:  IJC Metab Endocr       Date:  2015-03

6.  BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

Authors:  Saul M Genuth; Helen Vlachos; Maria Mori Brooks; John P Bantle; Bernard R Chaitman; Jennifer Green; Sheryl F Kelsey; Spencer B King; Robert McBane; Edward Y Sako; David J Schneider; Michael Steffes; Robert L Frye
Journal:  Mayo Clin Proc       Date:  2019-10-04       Impact factor: 7.616

7.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

8.  Monocyte-platelet aggregates and CD11b expression as markers for thrombogenicity in atrial fibrillation.

Authors:  Christian Pfluecke; Daniel Tarnowski; Lina Plichta; Katharina Berndt; Paul Schumacher; Stefan Ulbrich; Mathias Forkmann; Marian Christoph; David M Poitz; Carsten Wunderlich; Ruth H Strasser; Karim Ibrahim
Journal:  Clin Res Cardiol       Date:  2015-09-28       Impact factor: 5.460

Review 9.  An update on the prognosis of patients with atrial fibrillation.

Authors:  David D McManus; Michiel Rienstra; Emelia J Benjamin
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

Review 10.  How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?

Authors:  Rajiv Sankaranarayanan; Graeme Kirkwood; Rajaverma Visweswariah; David J Fox
Journal:  Curr Cardiol Rev       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.